Thermo Fisher Scientific market cap is $206.1 b, and annual revenue was $32.22 b in FY 2020

Thermo Fisher Scientific Revenue growth (FY, 2019 - FY, 2020), %26%

Thermo Fisher Scientific Gross profit (FY, 2020)16.5 B

Thermo Fisher Scientific Gross profit margin (FY, 2020), %51.2%

Thermo Fisher Scientific Net income (FY, 2020)6.4 B

Thermo Fisher Scientific EBIT (FY, 2020)7.8 B

Thermo Fisher Scientific Cash, 31-Dec-202010.3 B

Thermo Fisher Scientific EV217.6 B

Thermo Fisher Scientific revenue was $32.22 b in FY, 2020 which is a 26.1% year over year increase from the previous period.

Thermo Fisher Scientific revenue breakdown by business segment: 35.1% from Laboratory Products and Services, 15.3% from Specialty Diagnostics, 14.7% from Analytical Instruments and 34.9% from Life Sciences Solutions

Thermo Fisher Scientific revenue breakdown by geographic segment: 8.7% from China, 51.0% from United States and 40.3% from Other

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Revenue | 24.4b | 25.5b | 32.2b |

| 16% | 5% | 26% |

## Cost of goods sold | 13.5b | 14.2b | 15.7b |

## Gross profit | 10.9b | 11.3b | 16.5b |

| 45% | 44% | 51% |

## R&D expense | 967.0m | 1.0b | 1.2b |

## General and administrative expense | 6.1b | 6.1b | 6.9b |

## Operating expense total | 10.9b | 7.1b | 8.1b |

## EBIT | 3.8b | 4.6b | 7.8b |

| 16% | 18% | 24% |

## Interest expense | 676.0m | 553.0m | |

## Interest income | 224.0m | 65.0m | |

## Pre tax profit | 3.3b | 4.1b | 7.2b |

## Income tax expense | 324.0m | 374.0m | 850.0m |

## Net Income | 2.9b | 3.7b | 6.4b |

## EPS | 7.2 | 9.2 | 16.0 |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 5.9b | 6.1b | 5.9b | 6.1b | 6.3b | 6.3b | 6.2b | 6.9b | 8.5b |

## Cost of goods sold | 3.3b | 3.3b | 3.3b | 2.4b | 3.5b | 3.5b | 3.5b | 3.4b | 4.2b |

## Gross profit | 2.6b | 2.7b | 2.6b | 3.7b | 2.8b | 2.8b | 2.7b | 3.5b | 4.3b |

| 44% | 45% | 44% | 61% | 45% | 44% | 44% | 51% | 51% |

## R&D expense | 234.0m | 242.0m | 240.0m | 248.0m | 246.0m | 247.0m | 245.0m | 264.0m | 296.0m |

## General and administrative expense | 1.5b | 1.5b | 1.5b | 1.5b | 1.6b | 1.5b | 1.6b | 1.4b | 1.6b |

## Operating expense total | 1.8b | 1.8b | 1.7b | 2.8b | 1.3b | 1.8b | 1.8b | 2.1b | 1.9b |

## EBIT | 786.0m | 937.0m | 912.0m | 920.0m | 1.5b | 946.0m | 906.0m | 1.4b | 2.4b |

| 13% | 15% | 15% | 15% | 24% | 15% | 15% | 20% | 28% |

## Interest expense | 126.0m | 137.0m | 144.0m | ||||||

## Interest income | 36.0m | 8.0m | 9.0m | ||||||

## Pre tax profit | 634.0m | 806.0m | 810.0m | 817.0m | 1.4b | 822.0m | 828.0m | 1.3b | 2.3b |

## Income tax expense | 55.0m | 54.0m | 101.0m | 2.0m | 274.0m | 62.0m | 40.0m | 97.0m | 319.0m |

## Net Income | 579.0m | 752.0m | 709.0m | 815.0m | 1.1b | 760.0m | 788.0m | 1.2b | 1.9b |

## EPS | 1.4 | 1.9 | 1.8 | 2.0 | 2.8 | 1.9 | 2.0 | 2.9 | 4.8 |

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Cash | 2.1b | 2.4b | 10.3b |

## Accounts Receivable | 4.1b | 4.3b | 5.7b |

## Inventories | 3.0b | 3.4b | 4.0b |

## Current Assets | 10.6b | 11.9b | 22.0b |

## PP&E | 4.2b | 4.7b | 5.9b |

## Goodwill | 25.3b | 25.7b | 26.0b |

## Total Assets | 56.2b | 58.4b | 69.1b |

## Accounts Payable | 1.6b | 1.9b | 2.2b |

## Short-term debt | 1.3b | 676.0m | 2.6b |

## Current Liabilities | 6.1b | 6.2b | 10.3b |

## Long-term debt | 17.7b | 17.1b | 19.1b |

## Non-Current Liabilities | 22.5b | 22.5b | |

## Total Debt | 19.0b | 17.8b | 21.7b |

## Total Liabilities | 28.6b | 28.7b | |

## Common Stock | 432.0m | 434.0m | 437.0m |

## Additional Paid-in Capital | 14.6b | 15.1b | 15.6b |

## Retained Earnings | 18.7b | 22.1b | 28.1b |

## Total Equity | 27.6b | 29.7b | 34.5b |

## Debt to Equity Ratio | 0.7 x | 0.6 x | 0.6 x |

## Debt to Assets Ratio | 0.3 x | 0.3 x | 0.3 x |

## Financial Leverage | 2 x | 2 x | 2 x |

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Net Income | 2.9b | 3.7b | 6.4b |

## Depreciation and Amortization | 2.3b | 2.3b | 2.3b |

## Accounts Receivable | (366.0m) | (225.0m) | (1.3b) |

## Inventories | (324.0m) | (458.0m) | (508.0m) |

## Accounts Payable | 201.0m | 266.0m | 59.0m |

## Cash From Operating Activities | 4.5b | 5.0b | 8.3b |

## Purchases of PP&E | (758.0m) | (926.0m) | (1.5b) |

## Cash From Investing Activities | (1.3b) | (1.5b) | (1.5b) |

## Long-term Borrowings | (2.1b) | (6.4b) | (1.1b) |

## Dividends Paid | (266.0m) | (297.0m) | (337.0m) |

## Cash From Financing Activities | (2.2b) | (3.1b) | 959.0m |

## Net Change in Cash | 756.0m | 305.0m | 7.9b |

USD | Q1, 2018 |
---|---|

## Debt/Equity | 0.8 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | 2.2 x |

Thermo Fisher Scientific's Customers was reported to be 400 k in FY, 2020. Thermo Fisher Scientific's Backlog was reported to be $7.8b in FY, 2019.

FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | |
---|---|---|---|---|

## Backlog | $4.46 b | $5.09 b | $7.77 b | |

## Backlog (Analytical Instruments) | $2.05 b | $2.24 b | $2.2 b | |

## Backlog (Laboratory Products and Services) | $1.68 b | $2.06 b | $4.58 b | |

## Backlog (Life Sciences Solutions) | $594 m | $647 m | $893 m | |

## Backlog (Specialty Diagnostics) | $158 m | $187 m | $172 m | |

## Customers | 400 k | 400 k | 400 k | 400 k |

## Remaining Performance Obligations | $12.81 b |

FY, 2019 | |
---|---|

## Сorporate Сontributions | 1.8 m |

## Waste Diverted from Landfills | 4.3 k tons |

## Volunteer Hours | 115 k |

Thermo Fisher Scientific's employees are reported to be approximately 41% female and 59% male.